Momentis Surgical News
18 articles
/PRNewswire/ -- Momentis Surgical Ltd., a leader in robotic-assisted surgical innovation, today announced the U.S. Food and Drug Administration (FDA) 510(k)...
Momentis Surgical Ltd. has received FDA 510(k) clearance for its second-generation Anovo robotic surgical platform. This platform, which builds on previous clinical insights, offers enhanced features such as improved ergonomics, integrated haptic feedback, and a new video overlay for better communication. The clearance marks a significant milestone in Momentis Surgicals plan to revolutionize robotic-assisted surgeries. The company aims to expand Anovos applications to include general surgery and broaden its presence in Europe and Asia. Backed by investors like Peregrine Ventures and OurCrowd, Momentis Surgical is poised to extend its reach beyond hospitals to outpatient centers, enhancing access to robotic surgery solutions.
Investment
/PRNewswire/ -- Momentis Surgical Ltd., a medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, today...
Momentis Surgical Ltd. has received FDA 510(k) clearance for its Anovo robotic surgical platform, marking a significant milestone in robotic surgery. The Anovo platform, designed for single-site abdominal access ventral hernia repair, is the first of its kind to be approved for this procedure in the U.S. The systems unique features, including flexible robotic arms and humanoid-shaped instruments, offer enhanced dexterity and reduced invasiveness, making it suitable for both hospital and outpatient settings. This approval expands Anovos applications beyond gynecology, potentially transforming general surgery practices. The company aims to make robotic surgery more accessible and cost-effective, benefiting surgeons and patients alike.
Expand
Momentis Surgical wins FDA clearance for its surgical robot
Momentis Surgical has received FDA 510(k) clearance for its Anovo robotic surgical platform, marking a significant milestone for the company. The Anovo system is now cleared for single-site, abdominal access in ventral hernia repair, expanding its previous approvals for gynecological procedures. This clearance positions Anovo as the first single-port robotic system approved for this indication. The systems small, portable design and biomimetic instruments offer less invasive surgical options, potentially broadening its use in both hospital and outpatient settings. Dr. Fred Moll, a board member at Momentis, highlights the systems flexibility and impact on general surgery. CEO Dvir Cohen emphasizes the opportunity to expand into general surgery, leveraging existing connections with medical centers worldwide.
CustomersExpand
Surgical robotics startup Momentis cutting 60% of team one year after $1 billion SPAC fell through | CTech
Momentis, formerly Memic, a surgical robotics company, is laying off 60% of its employees, reducing the workforce from 120 to 50 employees. The layoffs are aimed at slowing down the cash burn rate and focusing on regulatory efforts to obtain FDA approval for a product for general surgery. Momentis had previously announced a merger with MedTech Acquisition Corporation, but the SPAC was canceled due to market conditions. The company has raised $116 million to date and has a focus on developing robotic-assisted surgery solutions. Momentis has an R&D center in Israel and an engineering center in the U.S. The companys first FDA approval was for use in single-site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures.
Layoffs
Momentis Announces First Adoption of Anovo™ Surgical System in Texas by Medical City Plano
Momentis Surgical has announced that Medical City Plano has acquired the Anovo Surgical System for transvaginal benign gynecological procedures. The Anovo System is the first FDA-authorized surgical robot with miniature humanoid-shaped arms. It enables minimally invasive transvaginal procedures and requires a smaller footprint and lower cost compared to conventional robotic systems. The adoption of this system by Medical City Plano represents a commercial milestone for Momentis Surgical. The company aims to broaden the availability of the system and improve gynecological surgery. Momentis Surgical is a medical device company founded in 2013 and based in Tel Aviv, Israel.
PartnersCustomers
Momentis Announces HCA Florida Northwest Hospital Acquires Anovo™ Surgical System
Momentis Surgical has announced that HCA Florida Northwest Hospital has acquired the Anovo Surgical System for use in transvaginal benign gynecological procedures. The Anovo System is the first and only FDA-authorized surgical robot with features designed to mimic human arms. The system offers several advantages compared to other available robotic technologies and enables minimally invasive surgery with benefits such as less pain, faster recovery, and reduced scarring. Momentis Surgical aims to build broader commercial adoption of the Anovo System and make the technology available to more women. HCA Florida Northwest Hospital is known for its advanced medical technology and focus on patient safety and care experience.
Customers
Momentis Announces Lee Health Adopts Anovo™ Surgical System for Robotic-Assisted Benign Gynecological Surgeries
Momentis Surgical has announced that Lee Health has acquired the Anovo Surgical System, the first FDA-authorized surgical robot with humanoid-shaped arms. The Anovo System enables a less invasive vaginal approach for gynecological procedures, resulting in faster recovery times, less pain, and virtually no visible scars. This acquisition is expected to have a growth-positive impact on Momentis Surgical. The Anovo System is indicated for use in single-site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures. It costs significantly less than conventional robotic systems and has a smaller footprint, making it accessible to more hospitals and surgery centers. The Anovo System was granted de novo marketing authorization from the FDA in February 2021.
Customers
Memic Innovative Surgery Announces its Rebrand to Momentis Surgical™ to Reflect Corporate Transformation
Memic Innovative Surgery Ltd. has rebranded to become Momentis Surgical and changed the name of its proprietary technology to Anovo Surgical System. The company showcased clinical data of the Anovo System at the SRS 2022 Annual Meeting, highlighting its applications in robotic-assisted transvaginal benign surgical procedures. The system offers optimal access and working angles, requires a smaller footprint, and costs significantly less than conventional robotic systems. Momentis aims to empower surgeons to perform minimally invasive, complex procedures and expand access to more surgeons, patients, hospitals, and surgery centers globally.
CustomersPartners
MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination
MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. have mutually agreed to terminate their previously announced business combination agreement due to market conditions and associated volatility. The termination has a growth-negative impact on MedTech. Memic is a medical device company focused on transforming surgery with its proprietary surgical robotic technology. The termination of the agreement is a key theme in the article. The structured issue is Partners, as the termination involves the end of a partnership between MedTech and Memic. The article does not mention any specific investors, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event. Confidence: 8
Partners
Memic Innovative Surgery Named to Fast Company's Annual List of World's 50 Most Innovative Companies for 2022
Memic Innovative Surgery Ltd. has been named to Fast Companys list of the Worlds Most Innovative Companies for 2022. The company is dedicated to transforming surgery with its proprietary surgical robotic technology. Memics Hominis Surgical System, the first and only FDA-authorized surgical robot with miniature humanoid-shaped arms, has been adopted by hospital systems in the U.S. The company has also announced a partnership with VirtaMed to develop a virtual reality simulator program for surgeon skills development. The recognition from Fast Company comes at a pivotal time for Memic as it expands its commercial footprint across the country.
PartnersExpand
Memic Innovative Surgery partners with VirtaMed to develop robotic surgery simulation
Memic מביאה את בשורת הרובוט הניתוחי לארה"ב: סגרה 3 עסקאות למכירת ה- Hominis ברבעון הרביעי של 2021 New-Tech OnLine
Israeli company Memic, which is nearing a merger with a SPAC at a valuation of $1 billion, continues to penetrate the American market and spread the news of the surgical robot it developed. The company, which develops robots designed to perform minimally invasive surgeries, closed three deals in the fourth quarter of 2021 to sell the robot, the Hominis, to three leading hospitals in the US. The three are: HCA Kendall Regional Medical Center; AdventHealth Celebration and the Womens Hospital at Jackson Memorial. All three hospitals are located in Florida, where Memic has a subsidiary.
CustomersPublic TradingAcquisition
Israeli medical device company Memic to merge with SPAC at more than $1 billion valuation
Memic Innovative Surgery, an Israeli medical device company specializing in robotic-assisted surgery, has announced a merger agreement with MedTech Acquisition Corporation, a publicly-traded special purpose acquisition company (SPAC) focused on medical technology. The combined company is expected to have an estimated pro-forma equity value of over $1 billion and approximately $360 million in cash. The merger is set to advance the robot-assisted surgery market and bring Memics advanced technology to medical facilities and patients worldwide. Memics FDA-authorized surgical robotic platform, the Hominis system, features miniature humanoid-shaped robotic arms that provide human-level dexterity and flexibility. The merger is expected to be completed in the fourth quarter of 2021.
AcquisitionPublic Trading
$1b SPAC deal seen for Israeli medical robotics co Memic
Memic Innovative Surgery, an Israeli medical robotics company, has raised $96 million and received FDA approval for its robotic device for transvaginal surgery. There are reports that the company may be merged into a SPAC called Medical Acquisition Corp, with a valuation of about $1 billion. The valuation is comparable to successful medical robotics companies Mazor Robotics and Corindus. The deal is seen as a positive sign for the technology market, particularly in the medical technology sector. The recent funding round was led by Peregrine Ventures and Ceros Ventures, with participation from Accelmed, OurCrowd, and Danny Hadar. Memic Innovative Surgerys device allows for surgery with fewer incisions and easier recovery for patients. The company has hired some of MAKO Surgicals team to build its sales force in the US.
AcquisitionPublic Trading
Israeli surgical robot co Memic raises $96m
Memic Innovative Surgery, an Israeli surgical robot company, has completed a $96 million Series D financing round led by Peregrine Ventures and Ceros. The funds will support the commercialization of Memics Hominis robotic-assisted surgical platform in the US and potentially other countries, as well as continued R&D and manufacturing scale-up. The Hominis system received FDA approval for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures. It features miniature humanoid-shaped robotic arms that provide human level dexterity and 360 degrees of articulation. The system will be sold at a significantly lower price compared to other robotic surgery systems, making it more accessible to medical facilities. The financing positions Memic to accelerate its commercialization efforts and bring Hominis to surgeons and patients in the coming months.
InvestmentExpand
Memic Receives FDA De Novo Marketing Authorization for First-Ever Surgical Robotic System with Humanoid-shaped Robotic Arms
Memic, a medical device company, has received FDA De Novo marketing authorization for its Hominis robot-assisted surgical platform. The authorization allows the company to use the platform for single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures, including benign hysterectomy. The Hominis system features miniature humanoid-shaped robotic arms that provide human-level dexterity and flexibility. It is the first and only FDA-authorized surgical robotic platform with these features. The system is also priced significantly lower than other robotic surgery systems. Memic plans to pursue additional surgical indications and is developing AI-enabled features. The company believes the authorization represents a significant advance in robot-assisted surgery and opens the door for expansion into new indications.
CustomersPartners
Israeli robotic arms get FDA nod for minimally invasive hysterectomies
Memic Innovative Surgery has received marketing authorization from the US FDA for its robotic surgical device, the Hominis Surgical System, which is used for transvaginal hysterectomies. The FDA authorization is based on clinical data from procedures performed in Belgium and Israel. The Hominis system features miniature humanoid-shaped robotic arms and offers a less invasive option for gynecologic surgery. The company plans to expand the use of the Hominis platform for other general surgery uses and is developing AI-enabled features. Memic has received seed funding of $950,000 from investors including Accelmed, OurCrowd, and Peregrine Ventures.
Customers
Ultrasound breakthrough allows doctors to examine patients remotely
Israeli company iNNOGING Medical has developed a new invention that allows physicians to manipulate captured ultrasound video and perform a virtual dynamic exam without the patient present. The technology converts ultrasound video clips into a 3D model, which doctors can navigate through using iNNOGINGs Probe & Pad hardware. The system aims to increase diagnostic accuracy and reduce medical costs by allowing doctors to analyze and manipulate recorded ultrasound images after the patient has left. iNNOGING Medical completed its first investment round within 100 days, receiving investments from angels and doctors. The company plans to commercialize its ultrasound simulator product within one year and launch its medical ultrasound analyzer in the US market within three years, pending FDA approval.
CustomersPartnersInvestmentExpand
